1.19
price up icon0.00%   0.00
after-market アフターアワーズ: 1.19
loading
前日終値:
$1.19
開ける:
$1.21
24時間の取引高:
95,904
Relative Volume:
1.24
時価総額:
$28.14M
収益:
-
当期純損益:
$-22.29M
株価収益率:
-1.0085
EPS:
-1.18
ネットキャッシュフロー:
$-17.12M
1週間 パフォーマンス:
-7.03%
1か月 パフォーマンス:
+9.17%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
-12.18%
1日の値動き範囲:
Value
$1.18
$1.235
1週間の範囲:
Value
$1.16
$1.31
52週間の値動き範囲:
Value
$0.8101
$1.76

Enlivex Therapeutics Ltd Stock (ENLV) Company Profile

Name
名前
Enlivex Therapeutics Ltd
Name
セクター
Healthcare (1161)
Name
電話
-
Name
住所
-
Name
職員
36
Name
Twitter
@EnlivexT
Name
次回の収益日
2024-09-09
Name
最新のSEC提出書
Name
ENLV's Discussions on Twitter

ENLV を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ENLV
Enlivex Therapeutics Ltd
1.19 30.53M 0 -22.29M -17.12M -1.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-03-02 繰り返されました H.C. Wainwright Buy

Enlivex Therapeutics Ltd (ENLV) 最新ニュース

pulisher
Jul 21, 2025

Enlivex Therapeutics Ltd. Stock Analysis and ForecastConsistently high yield - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

What drives Enlivex Therapeutics Ltd. stock priceOutstanding capital returns - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Enlivex Therapeutics Ltd. stockExtraordinary market timing - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Is Enlivex Therapeutics Ltd. a good long term investmentRapid return acceleration - Autocar Professional

Jul 19, 2025
pulisher
Jul 16, 2025

why enlivex therapeutics ltd. stock attracts strong analyst attentionLow Risk Entry Points - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Why Enlivex Therapeutics Ltd. stock attracts strong analyst attentionReal Trader Insights - beatles.ru

Jul 16, 2025
pulisher
Jul 16, 2025

How Enlivex Therapeutics Ltd. stock performs during market volatilityPrecision Entry Strategy - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Enlivex Therapeutics Ltd. stock price move sharplyReturn Maximized Portfolio Strategy - Newser

Jul 15, 2025
pulisher
Jun 17, 2025

Sepsis Market Growth to Accelerate in Forecast Period - openPR.com

Jun 17, 2025
pulisher
Jun 13, 2025

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian

Jun 13, 2025
pulisher
Jun 13, 2025

Trust Consulting Services CEO James Radford Named One of CIO Bulletin's "Best Entrepreneurs to Watch 2025" - Marco Eagle

Jun 13, 2025
pulisher
Jun 13, 2025

Unusual Machines Announces Termination of Definitive Agreement to Acquire Aloft - The Holland Sentinel

Jun 13, 2025
pulisher
Jun 13, 2025

Safe 'N' Sound Environmental Services Ltd. Recognized with 2025 Consumer Choice Award for Asbestos Removal in Halton Region - Sarasota Herald-Tribune

Jun 13, 2025
pulisher
Jun 11, 2025

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar

Jun 11, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics (ENLV) to Present Promising Allocetra Data at EULAR Congress | ENLV Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics to Present Clinical Data of Allocetra in Os - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona - Nasdaq

Jun 10, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - The Manila Times

Jun 10, 2025
pulisher
Jun 10, 2025

Breakthrough Cell Therapy Shows Promise in Knee Osteoarthritis: Enlivex Phase I/II Trial Data at EULAR 2025 - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions - Reno Gazette Journal

Jun 10, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Acquires New Holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World

Jun 06, 2025
pulisher
Jun 02, 2025

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - El Paso Times

Jun 02, 2025
pulisher
May 30, 2025

Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks

May 30, 2025
pulisher
May 29, 2025

D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud

May 29, 2025
pulisher
May 29, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World

May 29, 2025
pulisher
May 28, 2025

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times

May 28, 2025
pulisher
May 21, 2025

ENLIVEX THERAPEUTICS Earnings Preview: Recent $ENLV Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 21, 2025
pulisher
May 20, 2025

Enlivex (ENLV) to Present Cell Therapy Advancements at Israeli B - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Revolutionary Cell Therapy Shows 47% Pain Reduction in Osteoarthritis: Enlivex Reveals Breakthrough Data - Stock Titan

May 20, 2025
pulisher
May 20, 2025

Enlivex Selected to Present at Israeli BioMed 2025 Conference - FinancialContent

May 20, 2025
pulisher
May 08, 2025

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers - Barchart.com

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Acquires 84,203 Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World

May 07, 2025
pulisher
May 02, 2025

Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire

May 02, 2025
pulisher
Apr 24, 2025

Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India

Apr 24, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World ... - Bluefield Daily Telegraph

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView

Apr 23, 2025
pulisher
Apr 23, 2025

Game-Changing Cell Therapy Helps Patients Avoid Knee Replacement: Clinical Trial Results Revealed - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo

Apr 22, 2025

Enlivex Therapeutics Ltd (ENLV) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
大文字化:     |  ボリューム (24 時間):